COVID-19 mild cases determination from correlating COVID-line calls to reported cases

08/03/2020 ∙ by Ezequiel Alvarez, et al. ∙ 0

Background: One of the most challenging keys to understand COVID-19 evolution is to have a measure on those mild cases which are never tested because their few symptoms are soft and/or fade away soon. The problem is not only that they are difficult to identify and test, but also that it is believed that they may constitute the bulk of the cases and could be crucial in the pandemic equation. Methods: We present a novel algorithm to extract the number of these mild cases by correlating a COVID-line calls to reported cases in given districts. The key assumption is to realize that, being a highly contagious disease, the number of calls by mild cases should be proportional to the number of reported cases. Whereas a background of calls not related to infected people should be proportional to the district population. Results: We find that for Buenos Aires Province, in addition to the background, there are in signal 6.6 +/- 0.4 calls per each reported COVID-19 case. Using this we estimate in Buenos Aires Province 20 +/- 2 COVID-19 symptomatic cases for each one reported. Conclusions: A very simple algorithm that models the COVID-line calls as sum of signal plus background allows to estimate the crucial number of the rate of symptomatic to reported COVID-19 cases in a given district. The result from this method is an early and inexpensive estimate and should be contrasted to other methods such as serology and/or massive testing.



There are no comments yet.


page 1

page 2

page 3

page 4

This week in AI

Get the week's most popular data science and artificial intelligence research sent straight to your inbox every Saturday.


  • [1] Kristian G. Andersen, Andrew Rambaut, W. Ian Lipkin, Edward C. Holmes and Robert F. Garry, ‘The proximal origin of SARS-CoV-2’. Nat Med 26, 450–452 (2020)
  • [2] Chih-Cheng Lai, Tzu-Ping Shih, Wen-Chien Ko, Hung-Jen Tang and Po-RenHsueh, ‘Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges’. Int. J. of Antimicrobial Agents, 55, 3, March 2020, 105924.
  • [3] Anthony S. Fauci, M.D., H. Clifford Lane, M.D., and Robert R. Redfield, M.D, ‘Covid-19 — Navigating the Uncharted’. N Engl J Med 2020; 382:1268-1269,
  • [4] Daniel P. Oran, AM, Eric J. Topol, MD, ‘Prevalence of Asymptomatic SARS-CoV-2 Infection’. Annals of Internal Medicine,
  • [5] Sang Woo Park, Daniel M.Cornforth, Jonathan Dushoff, Joshua S.Weitz, ‘The time scale of asymptomatic transmission affects estimates of epidemic potential in the COVID-19 outbreak’. Epidemicsi, 31, June 2020, 100392,
  • [6] Ginsberg, J., Mohebbi, M., Patel, R. et al. ‘Detecting influenza epidemics using search engine query data’. Nature 457, 1012–1014 (2009).
  • [7] S.J.Yan, A.A.Chughtai and C.R.Macintyre, ‘Utility and potential of rapid epidemic intelligence from internet-based sources’. International Journal of Infectious Diseases, 63, 2017, pp 77-87,
  • [8] M. Tanabashi et al. [Particle Data Group], ‘Review of Particle Physics,’ Phys. Rev. D 98 (2018) no.3, 030001
  • [9] Deutsche Welle, May 4th 2020, (article link).
  • [10] El Pais, Spain, April 8th 2020, (article link).
  • [11] London, May 21st 2020, Health Secretary communication (article link).
  • [12] World Health Organization report, June 11th 2020 (link to bulletin).
  • [13] Kenji Mizumoto, Katsushi Kagaya, Alexander Zarebski, Gerardo Chowell. ‘Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship’, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):pii=2000180.
  • [14] Duaa W. Al-Sadeq, Gheyath K. Nasrallah, ‘The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review’. Int J Infect Dis. 2020 Jul 2,